Jin-Ming Yu

List of Publications by Year
in descending order

233 papers	4,988 citations	101543 36 h-index	155660 55 g-index
236 all docs	236 docs citations	236 times ranked	7302 citing authors

#	Article	IF	Citations
1	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 87.	8.6	213
2	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Letters, 2018, 414, 166-173.	7.2	207
3	Redox homeostasis maintained by GPX4 facilitates STING activation. Nature Immunology, 2020, 21, 727-735.	14.5	188
4	Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. Journal of Hematology and Oncology, 2017, 10, 81.	17.0	114
5	Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyteâ€“associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Translational Research, 2015, 166, 721-732.e1.	5.0	95
6	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biology and Medicine, 2019, 16, 655-670.	3.0	95
7	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. Cancer Letters, 2017, 405, 29-37.	7.2	93
8	The landscape of bispecific T cell engager in cancer treatment. Biomarker Research, 2021, 9, 38.	6.8	90
9	Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Letters, 2015, 365, 23-29.	7.2	84
10	Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Journal of Nuclear Medicine, 2006, 47, 1255-9.	5.0	83
11	ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Science Advances, 2021, 7, eabf6290.	10.3	79
12	The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis. Scientific Reports, 2017, 7, 4231.	3.3	67
13	A good start of immunotherapy in esophageal cancer. Cancer Medicine, 2019, 8, 4519-4526.	2.8	67
14	The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. Oncotarget, 2017, 8, 26368-26379.	1.8	64
15	HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium. Oncogene, 2019, 38, 868-880.	5.9	62
16	Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Letters, 2018, 418, 1-9.	7.2	61
17	Proton beam therapy for cancer in the era of precision medicine. Journal of Hematology and Oncology, 2018, 11, 136.	17.0	61
18	Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. Frontiers in Immunology, 2020, 11, 1088.	4.8	61

#	Article	IF	Citations
19	Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. American Journal of Cancer Research, 2015, 5, 2064-74.	1.4	60
20	MiRâ€216aâ€3p inhibits colorectal cancer cell proliferation through direct targeting COXâ€2 and ALOX5. Journal of Cellular Biochemistry, 2018, 119, 1755-1766.	2.6	59
21	miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. Oncology Reports, 2017, 37, 1093-1099.	2.6	57
22	Boschniakia Rossica Polysaccharide Triggers Laryngeal Carcinoma Cell Apoptosis by Regulating Expression of Bcl-2, Caspase-3, and P53. Medical Science Monitor, 2017, 23, 2059-2064.	1.1	54
23	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 67.	17.0	54
24	Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0157836.	2.5	53
25	Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer. European Radiology, 2019, 29, 2958-2967.	4.5	52
26	Feasibility of Involved-Field Conformal Radiotherapy for Cervical and Upper-Thoracic Esophageal Cancer. Onkologie, 2011, 34, 599-604.	0.8	49
27	The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer. OncoTargets and Therapy, 2016, Volume 9, 6529-6537.	2.0	49
28	Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of nonâ€“small cell lung cancer cells. Chinese Journal of Cancer, 2016, 35, 50.	4.9	48
29	Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2. Biomedicine and Pharmacotherapy, 2020, 125, 109964.	5.6	46
30	Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy. Oncotarget, 2016, 7, 48607-48613.	1.8	45
31	Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2017, 66, 343-354.	4.2	42
32	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget, 2016, 7, 71455-71465.	1.8	42
33	Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. Melanoma Research, 2019, 29, 77-84.	1.2	41
34	Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?. Journal of Nuclear Medicine, 2016, 57, 524-529.	5.0	40
35	Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. Oncotarget, 2016, 7, 64318-64329.	1.8	40
36	Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget, 2017, 8, 13304-13311.	1.8	40

#	Article	IF	Citations
37	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer After Previous Systemic Treatment Failureâ€”A Retrospective Study. Frontiers in Oncology, 2021, 11, 628124.	2.8	39
38	Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiation Oncology, 2014, 9, 64.	2.7	38
39	Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget, 2017, 8, 20510-20515.	1.8	37
40	Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients. Future Oncology, 2018, 14, 1187-1196.	2.4	37
41	The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study. Future Oncology, 2018, 14, 1397-1407.	2.4	36
42	Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. Radiation Oncology, 2016, 11, 18.	2.7	34
43	Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer. Future Oncology, 2019, 15, 995-1006.	2.4	33
44	Combined treatment of nonâ€small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Communications, 2021, 41, 1086-1099.	9.2	33
45	18F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2336-2342.	6.4	32
46	mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes. Journal of Cancer, 2017, 8, 646-656.	2.5	32
47	PET/CT imaging-guided dose painting in radiation therapy. Cancer Letters, 2014, 355, 169-175.	7.2	31
48	Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. , 2021, 9, e001865.		31
49	Changes in Functional Lung Regions During the Course of Radiation Therapy and Their Potential Impact on Lung Dosimetry for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 145-151.	0.8	30
50	Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing <scp>FGFR</scp>2 signalling. Journal of Cellular and Molecular Medicine, 2018, 22, 5596-5606.	3.6	30
51	Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 2643-2650.	2.4	30
52	miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs. Laboratory Investigation, 2019, 99, 568-576.	3.7	30
53	Antiâ€PDâ€L1/TGFâ€Î²R fusion protein (SHRâ€1701) overcomes disrupted lymphocyte recoveryâ€induced resistance to PDâ€1/PDâ€L1 inhibitors in lung cancer. Cancer Communications, 2022, 42, 17-36.	9.2	30
54	An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib. Radiotherapy and Oncology, 2020, 152, 96-100.	0.6	29

#	Article	IF	Citations
55	Computed Tomography-Based Delta-Radiomics Analysis for Discriminating Radiation Pneumonitis in Patients With Esophageal Cancer After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 111, 443-455.	0.8	29
56	Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thoracic Cancer, 2018, 9, 726-735.	1.9	28
57	Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC. International Immunopharmacology, 2019, 72, 395-401.	3.8	28
58	A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092682.	3.2	28
59	Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. Cancer Medicine, 2021, 10, 3-14.	2.8	28
60	[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1671-1681.	6.4	28
61	Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail. Radiotherapy and Oncology, 2013, 109, 275-280.	0.6	27
62	Fucoidan Promotes Apoptosis and Inhibits EMT of Breast Cancer Cells. Biological and Pharmaceutical Bulletin, 2019, 42, 442-447.	1.4	27
63	[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2761-2773.	6.4	26
64	The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer. Journal of Translational Medicine, 2019, 17, 402.	4.4	25
65	Prognostic value of 3â€²-Deoxy-3â€²-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas. Nuclear Medicine and Biology, 2014, 41, 710-715.	0.6	24
66	Intraâ€tumour ¹⁸<scp>F</scp>â€<scp>FDG</scp> uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 338-345.	1.8	24
67	Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients . Cancer Management and Research, 2019, Volume 11, 3153-3162.	1.9	24
68	Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Management and Research, 2018, Volume 10, 13-21.	1.9	23
69	The Role of Radiation Oncology in Immuno-Oncology. Oncologist, 2019, 24, S42-S52.	3.7	23
70	Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 940-947.	6.4	23
71	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Management and Research, 2018, Volume 10, 2475-2488.	1.9	22
72	The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with nonâ€smallâ€cell lung cancerâ€a retrospective study from one single cancer institute. Cancer Medicine, 2019, 8, 2769-2776.	2.8	22

#	Article	IF	Citations
73	Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP. Cancer Letters, 2021, 519, 150-160.	7.2	22
74	Value of¹⁸F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations. World Journal of Gastroenterology, 2014, 20, 6608.	3.3	22
75	A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer. Scientific Reports, 2017, 7, 2877.	3.3	21
76	A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1098-1106.	0.8	20
77	Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature. Frontiers in Oncology, 2020, 10, 561.	2.8	20
78	Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget, 2016, 7, 81906-81917.	1.8	20
79	A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. PLoS ONE, 2016, 11, e0157606.	2.5	19
80	The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. Oncotarget, 2017, 8, 33736-33744.	1.8	19
81	A Novel Nomogram and Risk Classification System Predicting Radiation Pneumonitis in Patients With Esophageal Cancer Receiving Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1074-1085.	0.8	19
82	Delineating the pattern of treatment for elderly locally advanced NSCLC and predicting outcomes by a validated model: A SEER based analysis. Cancer Medicine, 2019, 8, 2587-2598.	2.8	19
83	The efficacy and possible mechanisms of immune checkpoint inhibitors in treating nonâ€small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Communications, 2021, 41, 1314-1330.	9.2	19
84	C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome. Journal of Cancer, 2016, 7, 587-594.	2.5	18
85	Preoperative radiation may improve the outcomes of resectable IIIA/N2 nonâ€smallâ€cell lung cancer patients: A propensity score matchingâ€based analysis from surveillance, epidemiology, and end results database. Cancer Medicine, 2018, 7, 4354-4360.	2.8	18
86	Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e190103.	5.9	18
87	A Nomogram to Predict Distant Metastasis for Patients with Esophageal Cancer. Oncology Research and Treatment, 2020, 43, 2-9.	1.2	18
88	Osimertinib (AZD9291) increases radioâ€sensitivity in EGFR T790M nonâ€small cell lung cancer. Oncology Reports, 2019, 41, 77-86.	2.6	17
89	Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 803247.	4.8	17
90	Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2019, 20, 1121-1126.	3.4	16

#	Article	IF	Citations
91	Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Future Oncology, 2019, 15, 625-635.	2.4	16
92	Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. Cancer Letters, 2021, 502, 166-179.	7.2	16
93	Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy. Oncotarget, 2017, 8, 81405-81418.	1.8	16
94	Validation study for the hypothesis of internal mammary sentinel lymph node lymphatic drainage in breast cancer. Oncotarget, 0, 7, 41996-42006.	1.8	16
95	Incorporation of circulating tumor cells and whole-body metabolic tumor volume of 18F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 596-604.	2.2	16
96	The Value of CBCT-based Tumor Density and Volume Variations in Prediction of Early Response to Chemoradiation Therapy in Advanced NSCLC. Scientific Reports, 2017, 7, 14650.	3.3	15
97	FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients WithÂBone Metastasis From Nonâ€“small-cell LungÂCancer. Clinical Lung Cancer, 2015, 16, e111-e119.	2.6	14
98	Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation. OncoTargets and Therapy, 2016, Volume 9, 4187-4196.	2.0	14
99	The expression of pâ€p62 and nuclear Nrf2 in esophageal squamous cell carcinoma and association with radioresistance. Thoracic Cancer, 2020, 11, 130-139.	1.9	14
100	Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy. Lung Cancer, 2021, 151, 39-43.	2.0	14
101	GINS2 attenuates the development of lung cancer by inhibiting the STAT signaling pathway. Journal of Cancer, 2021, 12, 99-110.	2.5	14
102	Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. Radiation Oncology, 2021, 16, 41.	2.7	14
103	Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget, 2016, 7, 52436-52441.	1.8	13
104	Extended field intensity-modulated radiotherapy plus concurrent nedaplatin treatment in cervical cancer. Oncology Letters, 2016, 11, 3421-3427.	1.8	13
105	Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer. Scientific Reports, 2017, 7, 42743.	3.3	13
106	Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment. Frontiers in Oncology, 2021, 11, 643654.	2.8	13
107	Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. Oncotarget, 2017, 8, 35262-35271.	1.8	13
108	The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 14969-14977.	1.8	13

#	Article	IF	Citations
109	False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature. Oncology Letters, 2015, 10, 3585-3590.	1.8	12
110	A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy. Breast Cancer Research and Treatment, 2017, 166, 109-116.	2.5	12
111	Comparison of predictive powers of functional and anatomic dosimetric parameters for radiation-induced lung toxicity in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2018, 129, 242-248.	0.6	12
112	Dosimetric and Radiobiological Comparison of External Beam Radiotherapy Using Simultaneous Integrated Boost Technique for Esophageal Cancer in Different Location. Frontiers in Oncology, 2019, 9, 674.	2.8	12
113	Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma . Cancer Management and Research, 2019, Volume 11, 2269-2280.	1.9	12
114	A_{2A}R Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. Journal of Cancer, 2020, 11, 3685-3692.	2.5	12
115	Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme. Journal of Oncology, 2021, 2021, 1-12.	1.3	12
116	Correlation of CD146 expression and clinicopathological characteristics in esophageal squamous cell carcinoma. Oncology Letters, 2014, 8, 859-863.	1.8	11
117	Circulating Tumor Cells Correlate with Recurrence in Stage III Small-cell Lung Cancer after Systemic Chemoradiotherapy and Prophylactic Cranial Irradiation. Japanese Journal of Clinical Oncology, 2014, 44, 948-955.	1.3	11
118	Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer. Oncology Letters, 2015, 10, 3123-3128.	1.8	11
119	Positive Effect of Higher Adult Body Mass Index on Overall Survival of Digestive System Cancers Except Pancreatic Cancer: A Systematic Review and Meta-Analysis. BioMed Research International, 2017, 2017, 1-15.	1.9	11
120	Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer. Journal of Cancer, 2017, 8, 3190-3197.	2.5	11
121	Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant nonâ€small cell lung cancer. International Journal of Cancer, 2018, 143, 212-224.	5.1	11
122	Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on 18F-FDG PET/CT in Patients With Limited-stage Small-cell Lung Cancer With Lymph Node Involvement. Clinical Lung Cancer, 2018, 19, e101-e108.	2.6	11
123	Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis. Future Oncology, 2018, 14, 2371-2381.	2.4	11
124	Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response. OncoTargets and Therapy, 2018, Volume 11, 2509-2517.	2.0	11
125	Risk Factors Associated with Precancerous Lesions of Esophageal Squamous Cell Carcinoma: a Screening Study in a High Risk Chinese Population. Journal of Cancer, 2019, 10, 3284-3290.	2.5	11
126	The value of magnetic resonance imaging in esophageal carcinoma: Tool or toy?. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 101-107.	1.1	11

#	Article	IF	Citations
127	A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators. Cancer Medicine, 2020, 9, 1430-1440.	2.8	11
128	Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma. Translational Cancer Research, 2020, 9, 3842-3853.	1.0	11
129	Three models that predict the efficacy of immunotherapy in Chinese patients with advanced nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 6291-6303.	2.8	11
130	Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2017, 12, e0170901.	2.5	11
131	Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1253-1261.	2.5	11
132	Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience. Frontiers in Immunology, 2022, 13, 832419.	4.8	11
133	ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy. Pathology Research and Practice, 2014, 210, 656-661.	2.3	10
134	To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer. Molecular Imaging and Biology, 2018, 20, 1061-1067.	2.6	10
135	Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis. BioMed Research International, 2019, 2019, 1-15.	1.9	10
136	How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy. Cancer Biology and Therapy, 2016, 17, 125-128.	3.4	9
137	Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review. Cancer Biology and Therapy, 2017, 18, 279-284.	3.4	9
138	Clinical value of carcinoembryonic antigen for predicting the incidence of brain metastases and survival in small cell lung cancer patients treated with prophylactic cranial irradiation. Cancer Management and Research, 2018, Volume 10, 3199-3205.	1.9	9
139	End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1591-1599.	2.5	9
140	A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer. OncoTargets and Therapy, 2018, Volume 11, 3785-3792.	2.0	9
141	Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases . Cancer Management and Research, 2019, Volume 11, 10083-10092.	1.9	9
142	Spatial Concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to 3â€²-[18F]Fluoro-3â€²-Deoxythymidine PET Images: a Basic Study Guided for PET-Based Radiotherapy Dose Painting. Molecular Imaging and Biology, 2019, 21, 713-721.	2.6	9
143	What Is the Appropriate Clinical Target Volume for Esophageal Squamous Cell Carcinoma? Debate and Consensus Based on Pathological and Clinical Outcomes. Journal of Cancer, 2016, 7, 200-206.	2.5	8
144	Prognostic value of the standardized uptake value maximum change calculated by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer. OncoTargets and Therapy, 2016, 9, 2993.	2.0	8

#	Article	IF	Citations
145	Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. Cancer Letters, 2018, 421, 59-62.	7.2	8
146	Magnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lung cancer patients after radiotherapy: A preliminary study. Thoracic Cancer, 2018, 9, 865-873.	1.9	8
147	Potential of Gd-EOB-DTPA as an imaging biomarker for liver injury estimation after radiation therapy. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 354-359.	1.3	8
148	Proposed revision of N categories to the 8th edition of the AJCC â€•TNM staging system for nonâ€surgical esophageal squamous cell cancer. Cancer Science, 2019, 110, 717-725.	3.9	8
149	Preparation study of indocyanine green-rituximab: A new receptor-targeted tracer for sentinel lymph node in breast cancer. Oncotarget, 2016, 7, 47526-47535.	1.8	8
150	18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 34498-34506.	1.8	8
151	Increased hippocampal TrkA expression ameliorates cranial radiationâ€induced neurogenesis impairment and cognitive deficit via PI3K/AKT signaling. Oncology Reports, 2020, 44, 2527-2536.	2.6	8
152	Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1165-1176.	0.8	8
153	Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more. Future Oncology, 2018, 14, 2131-2138.	2.4	7
154	Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma. Oncology Reports, 2018, 40, 2906-2915.	2.6	7
155	Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study . OncoTargets and Therapy, 2019, Volume 12, 1681-1689.	2.0	7
156	Combination therapy. Medicine (United States), 2019, 98, e18030.	1.0	7
157	Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review. Lung Cancer, 2020, 139, 18-21.	2.0	7
158	Nanoparticle albuminâ€bound paclitaxel in elder patients with advanced squamous nonâ€smallâ€cell lung cancer: A retrospective study. Cancer Medicine, 2020, 9, 1365-1373.	2.8	7
159	Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study. Oncotarget, 2016, 7, 75492-75502.	1.8	7
160	Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy. BMC Gastroenterology, 2022, 22, 211.	2.0	7
161	The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. Virulence, 2022, 13, 1101-1110.	4.4	7
162	Anatomic distribution of supraclavicular lymph node in patients with esophageal cancer. OncoTargets and Therapy, 2016, Volume 9, 5803-5808.	2.0	6

#	Article	IF	Citations
163	Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. OncoTargets and Therapy, 2016, Volume 9, 4639-4644.	2.0	6
164	18Fâ€'alfatide positron emission tomography may predict antiâ€'angiogenic responses. Oncology Reports, 2018, 40, 2896-2905.	2.6	6
165	Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?. Frontiers in Immunology, 2018, 9, 2916.	4.8	6
166	Effectiveness of temozolomide combined with whole brain radiotherapy for nonâ€small cell lung cancer brain metastases. Thoracic Cancer, 2018, 9, 1121-1128.	1.9	6
167	Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastatic non-small-cell lung cancer. Future Oncology, 2019, 15, 1593-1603.	2.4	6
168	Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression. Frontiers in Immunology, 2021, 12, 633534.	4.8	6
169	Long nonâ€'coding RNA transcribed from pseudogene PPIAP43 is associated with radiation sensitivity of small cell lung cancer cells. Oncology Letters, 2019, 18, 4583-4592.	1.8	6
170	An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators. Bioorganic and Medicinal Chemistry, 2020, 28, 115607.	3.0	5
171	Enhanced radiosensitizing by sodium glycididazole in a recurrent esophageal carcinoma tumor model. Oncotarget, 2017, 8, 63871-63880.	1.8	5
172	High expression level of peptidylprolyl isomerase A is correlated with poor prognosis of liver hepatocellular carcinoma. Oncology Letters, 2019, 18, 4691-4702.	1.8	5
173	Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation. Cancer Research and Treatment, 2022, 54, 1209-1218.	3.0	5
174	Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation. OncoTargets and Therapy, 2016, 9, 671.	2.0	4
175	Orbital metastasis as the initial presentation of lung adenocarcinoma: a case report. OncoTargets and Therapy, 2016, 9, 2743.	2.0	4
176	Stereotactic Comparison Study of 18F-Alfatide and 18F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model. Scientific Reports, 2016, 6, 28757.	3.3	4
177	Current progress and outcomes of clinical trials on using epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy in nonâ€small cell lung cancer patients with brain metastases. Chronic Diseases and Translational Medicine, 2017, 3, 221-229.	1.2	4
178	Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Current Medical Science, 2017, 37, 864-872.	1.8	4
179	Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: a population-based, propensity-matched study. Cancer Management and Research, 2018, Volume 11, 339-346.	1.9	4
180	Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report. Cancer Biology and Therapy, 2018, 19, 1073-1077.	3.4	4

#	Article	IF	Citations
181	¹⁸F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients. OncoTargets and Therapy, 2018, Volume 11, 4345-4353.	2.0	4
182	A nomogram for the predicting of survival in patients with esophageal squamous cell carcinoma undergoing definitive chemoradiotherapy. Annals of Translational Medicine, 2021, 9, 233-233.	1.7	4
183	Identification of risk factors and the pattern of lower cervical lymph node metastasis in esophageal cancer: implications for radiotherapy target delineation. Oncotarget, 2017, 8, 43389-43396.	1.8	4
184	A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population. Oncotarget, 2017, 8, 94738-94742.	1.8	4
185	Survival prediction models for patients with anal carcinoma receiving definitive chemoradiation: A populationâ€based study. Oncology Letters, 2020, 19, 1443-1451.	1.8	4
186	The effect of TKI therapy and chemotherapy treatment delivery sequence on total progressionâ€free survival in patients with advanced EGFRâ€mutated NSCLC. Oncology Letters, 2020, 20, 391-400.	1.8	4
187	IDH1 Mutation Induces HIF-1Î± and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells. Disease Markers, 2022, 2022, 1-11.	1.3	4
188	Mapping patterns of nodal metastases in esophageal carcinoma: rethinking the clinical target volume for supraclavicular nodal irradiation. Journal of Thoracic Disease, 2016, 8, 3132-3138.	1.4	3
189	SRS versus WBRT for resected brain metastases. Lancet Oncology, The, 2017, 18, e559.	10.7	3
190	Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases. Cancer Management and Research, 2018, Volume 10, 6421-6429.	1.9	3
191	Axillary management still needed for patients with sentinel node micrometastases . Cancer Management and Research, 2019, Volume 11, 2097-2100.	1.9	3
192	Safety of thoracic radiotherapy after PDâ€(L)1 inhibitor treatment in patients with lung cancer. Cancer Medicine, 2021, 10, 8518-8529.	2.8	3
193	Inhibition of janus kinase 2 by compound AG490 suppresses the proliferation of MDA-MB-231 cells via up-regulating SARI (suppressor of AP-1, regulated by IFN). Iranian Journal of Basic Medical Sciences, 2015, 18, 599-603.	1.0	3
194	High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 2675-2682.	0.5	3
195	Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Journal of Translational Medicine, 2022, 20, 63.	4.4	3
196	Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer. Journal of Immunology Research, 2022, 2022, 1-8.	2.2	3
197	High-dose OxyContin to treat pain associated with bone metastasis in patients with small-cell lung cancer: a case study report. Drug Design, Development and Therapy, 2016, 10, 383.	4.3	2
198	To Find a Better Dosimetric Parameter in the Predicting of Radiation-Induced Lung Toxicity Individually: Ventilation, Perfusion or CT based. Scientific Reports, 2017, 7, 44646.	3.3	2

#	Article	IF	Citations
199	Internal mammary sentinel lymph node biopsy: An effective way to search benefit patients and guide internal mammary chain irradiation. Breast, 2017, 33, 204-205.	2.2	2
200	Is it time to convert the frequency of radiotherapy in small-cell lung cancer?. Lancet Oncology, The, 2017, 18, e553.	10.7	2
201	Effects of respiratory motion on volumetric and positional difference of GTV in lung cancer based on 3DCT and 4DCT scanning. Oncology Letters, 2019, 17, 2388-2392.	1.8	2
202	The flow-metabolism ratio might predict treatment response and survival in patients with locally advanced esophageal squamous cell carcinoma. EJNMMI Research, 2020, 10, 57.	2.5	2
203	Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.. Journal of Clinical Oncology, 2022, 40, 8563-8563.	1.6	2
204	Reversion of erlotinib-acquired resistance twice by chemotherapy. Cancer Biology and Therapy, 2014, 15, 172-177.	3.4	1
205	Postoperative radiation therapy of pT2-3N0M0 esophageal carcinomaâ€“a review. Tumor Biology, 2016, 37, 14443-14450.	1.8	1
206	Unusual delayed presentation of diaphragmatic hernia complicated by transverse colon and total small-bowel obstruction after postoperative chemotherapy of esophageal cancer. Therapeutics and Clinical Risk Management, 2017, Volume 13, 691-695.	2.0	1
207	Subclinical Lesions of the Primary Clinical Target Volume Margin in Esophageal Squamous Cell Carcinoma and Association With FDG PET/CT. Frontiers in Oncology, 2019, 9, 336.	2.8	1
208	A 4-month-old boy with gastrointestinal stromal tumor of mesocolon. Cancer Biology and Therapy, 2019, 20, 8-14.	3.4	1
209	Left Ventricular Systolic Dysfunction Is a Possible Independent Risk Factor of Radiation Pneumonitis in Locally Advanced Lung Cancer Patients. Frontiers in Oncology, 2019, 9, 1511.	2.8	1
210	Prediction of the effects of radiation therapy in esophageal cancer using diffusion and perfusion MRI. Cancer Science, 2021, 112, 5046-5054.	3.9	1
211	Comparison of different width detector on the gross tumor volume delineation of the solitary pulmonary lesion. Journal of Cancer Research and Therapeutics, 2017, 13, 693.	0.9	1
212	Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed. Oncotarget, 2017, 8, 74910-74916.	1.8	1
213	Precision regimen for personalized pancreatic cancer therapy. Precision Radiation Oncology, 2017, 1, 44-45.	1.1	0
214	The feasibility of non-contrast enhanced plus contrast-enhanced computed tomography in discriminating invasive pure ground-glass opacity from pre-invasive pure ground-glass opacity. Journal of Cardiothoracic Surgery, 2020, 15, 162.	1.1	0
215	Elevated serum carcinoembryonic antigen and prediction of poor survival of patients with small cell lung cancer.. Journal of Clinical Oncology, 2015, 33, e18561-e18561.	1.6	0
216	Stereotactic comparison study of 18F-Alfatide and 18F-FDG PET imaging in LLC tumor-bearing C57BL/6 mice model.. Journal of Clinical Oncology, 2016, 34, e20070-e20070.	1.6	0

#	Article	IF	Citations
217	Inhibition of hypoxia-inducible factor-1Î± by PX-478 as a potential targeted therapy in ESCC.. Journal of Clinical Oncology, 2017, 35, e14083-e14083.	1.6	0
218	Prognostic significance of the lymphocyteâ€toâ€monocyte ratio and the tumorâ€infiltrating lymphocyte to tumorâ€associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2017, 35, e15602-e15602.	1.6	0
219	Spatial concordance of tumor proliferation and accelerated repopulation from pathologic images to 18F-FLT PET images.. Journal of Clinical Oncology, 2017, 35, e23100-e23100.	1.6	0
220	Association of CD8+/FOXP3+ ratio and PD-L1 expression with survival in pT3N0M0 stage esophageal squamous cell cancer.. Journal of Clinical Oncology, 2017, 35, e15517-e15517.	1.6	0
221	A prospective study on neoadjuvant chemoradiotherapy plus nimotuzumab followed by surgery for patients with advanced cervical cancer.. Journal of Clinical Oncology, 2017, 35, e17000-e17000.	1.6	0
222	A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy. Oncotarget, 2018, 9, 385-393.	1.8	0
223	Association between heart dosimetric parameters, cardiac events and overall survival for patients with stage III esophageal cancer treated with definitive radiotherapy.. Journal of Clinical Oncology, 2019, 37, e15561-e15561.	1.6	0
224	Apatinib in the treatment of non-operable or advanced gastric cancer: Evidence of efficacy and safety in a real-world study.. Journal of Clinical Oncology, 2019, 37, e15515-e15515.	1.6	0
225	Interleukin-2 boosts local and abscopal antitumor effect of radiotherapy combined with anti-PD-1: A translational research from clinical radio-memory effect.. Journal of Clinical Oncology, 2019, 37, e14244-e14244.	1.6	0
226	Primary tumor location as an important predictor for survival in pulmonary adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e20000-e20000.	1.6	0
227	Dosimetric and radiobiological comparison of external beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different location.. Journal of Clinical Oncology, 2019, 37, e15505-e15505.	1.6	0
228	Derived neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio as a prognostic marker for patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.. Journal of Clinical Oncology, 2019, 37, e15575-e15575.	1.6	0
229	Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study.. Journal of Clinical Oncology, 2020, 38, e21628-e21628.	1.6	0
230	Prognostic biomarker candidates of neoadjuvant chemotherapy for luminal B-positive locally advanced breast cancer.. Journal of Clinical Oncology, 2020, 38, e12638-e12638.	1.6	0
231	Screening of potential genes and transcription factors involved in post-radiation cognitive dysfunction in mice via bioinformatics. Translational Cancer Research, 2020, 9, 6383-6391.	1.0	0
232	Progress of radiation oncology: known and unknown. Chinese Medical Journal, 2014, 127, 2173-9.	2.3	0
233	Abstract 6114: Prognostic value of the tumor-infiltrating lymphocytes in Miller-Payne grade 4 triple-negative breast cancer following neoadjuvant chemotherapy. Cancer Research, 2022, 82, 6114-6114.	0.9	0